BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript
Source: SeekingAlpha
2025-12-09 21:27:03 ET
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease December 9, 2025 4:15 PM EST...
Read the full article on Seeking Alpha
For further details see:
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript
BioVie Inc.
NASDAQ: BIVI
BIVI Trading
4.47% G/L:
$1.3999 Last:
22,680 Volume:
$1.39 Open:
BIVI Latest News
February 23, 2026 08:00:00 am
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4
February 12, 2026 08:00:00 am
BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
January 08, 2026 08:00:00 am
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease
BIVI Stock Data
$8,825,978
7,475,679
24.33%
13
N/A
Biotechnology & Life Sciences
Healthcare
US
Carson City
